Naloxone Market - Size, Industry Share, Growth Trends and Forecasts (2023 - 2031)

By Strength :

The strength is categorized into 2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and others. In 2022, the 2.0 mg/0.1 ml and 4.0 mg/ml segment accounted for the highest market share in the naloxone market. The 2.0 mg/0.1 ml and 4.0 mg/ml strengths of naloxone are largely used because they are the most effective and widely available formulations of this life-saving medication. The 2.0 mg/0.1 ml strength is typically used in nasal spray formulations, while the 4.0 mg/ml strength is typically used in injectable formulations. Both formulations are effective in reversing opioid overdoses, but the injectable formulation is more rapid-acting and may be preferred in critical situations. Both the 2.0 mg/0.1 ml and 4.0 mg/ml strengths of naloxone are safe and effective, and they have no potential for abuse. They are also relatively inexpensive, which makes them accessible to a wide range of people. Thus, the high accessibility and high benefits of these strengths are driving the segment growth across the globe.

Moreover, the 0.4 mg/ml segment is expected to hold the highest CAGR over the forecast period. The 0.4 mg/ml injectable solution is the most widely available form of naloxone, and it is also the most used form in clinical settings. It can be administered intramuscularly, subcutaneously, or intravenously. Moreover, the 0.4 mg/ml injectable solution is a safe and effective way to reverse an opioid overdose. It is also relatively inexpensive and easy to use. These factors are expected to contribute to the rapid growth of the market for this formulation of naloxone over the forecast period.

By Route of Administration :

The end-user industry segment is categorized into injectables nasal, and oral. In 2022, the injectables segment accounted for the highest market share in the overall naloxone market. The injectables segment is further categorized into intramuscular or subcutaneous and intravenous. Injectables are the dominant route of administration for naloxone because they are the most effective and rapid-acting way to deliver the medication. Injectable naloxone can be administered intramuscularly, subcutaneously, or intravenously. All three routes of administration are effective, but intravenous administration is the fastest act. The increasing launch of injectable naloxone medications is driving the segment growth across the globe. For instance, in January 2023, Hikma, a multinational pharmaceutical company, has launched Naloxone Hydrochloride Injection, USP, 2mg/2mL, in prefilled syringe (PFS) form in the US. This is the third PFS product launched by Hikma. The drug is used for the emergency treatment of a known or suspected opioid overdose. Thus, the high benefits of injectable naloxone along with the increasing product innovations is driving the segment growth worldwide.

Moreover, the nasal segment is expected to hold the highest CAGR over the forecast period. Nasal naloxone is a widely available form of naloxone that is easy to administer and does not require medical training. The increasing acceptance of the nasal route of administration of naloxone is expected to provide lucrative growth opportunities for the nasal route of administration over the forecast period. For instance, in March 2023, Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, the generic version of Narcan®. Naloxone is used to treat known or suspected opioid overdose emergencies. The growing acceptance of the nasal route of administration of naloxone is creating lucrative growth opportunities for segment growth over the forecast period.

By Distribution Channel :

The distribution channel segment is categorized into hospital pharmacies, retail stores, online pharmacies, and others. In 2022, the hospital pharmacies segment accounted for the highest market share of 39.72% in the overall naloxone market, and it is also expected to hold the highest CAGR over the forecast period. Hospitals are the primary setting where opioid overdoses are treated. Hospital pharmacies are responsible for dispensing naloxone to medical professionals to use in treating these overdoses. In the United States, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requires all hospitals to stock naloxone. This requirement is intended to ensure that naloxone is readily available to treat opioid overdoses in the hospital setting. Hospital pharmacies play an important role in the distribution of naloxone which is a key factor driving the segment growth across the globe.

Naloxone Market Regional Analysis:

The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 38.55% valued at USD 327.70 Million in 2022 and USD 362.96 Million in 2023, it is expected to reach USD 844.26 Million in 2031. In North America, the U.S. accounted for the highest market share of 62.38% during the base year of 2022. The increasing cases of opioids involved overdose cases across the region is the key factor driving the market growth across North America. For instance, according to the report by the National Institute on Drug Abuse in April 2023, opioid-involved overdose deaths in the United States rose from 21,089 in 2010 to 47,600 in 2017. The number of deaths remained steady through 2019. In 2020, there were 68,630 reported deaths, and in 2021, there were 80,411 reported deaths. Thus, the increase in opioid-involved overdose deaths is driving the demand for naloxone across North America region.

Furthermore, Asia Pacific is expected to witness significant growth over the forecast period, growing at a CAGR of 11.7% during 2023-2023. The significant growth in the pharmaceutical and drug industry across the region is providing lucrative growth opportunities for the market growth over the forecast period. For instance, according to the report by the National Investment Promotion and Facilitation Agency in April 2023, India's API industry is the third largest in the world. It contributes about 35% of the global pharmaceutical market. API stands for Active Pharmaceutical Ingredient, which is the biologically active component of a drug that causes an intended medical effect. All these above-mentioned factors are collectively boosting the market for naloxone across the Asia Pacific region and creating lucrative growth opportunities for the naloxone market in the Asia Pacific region.